Drug intelligence / Profile preview

oliclinomel n7-1000

Development stage
Unknown
Lead developer
Takeda
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Intravenous
01

Overview

Oliclinomel N7-1000 is a triple-chamber intravenous emulsion for parenteral nutrition in adults and children over 2 years of age when oral or enteral nutrition is impossible, insufficient, or contraindicated. Each chamber contains a different component—amino acids (including essential and non-essential amino acids), glucose (with or without electrolytes), and an olive oil/soya oil-based lipid emulsion rich in omega-9 fatty acids. The product provides balanced macronutrients to promote nitrogen balance and replenish protein reserves during catabolic states such as extensive burns or protein-calorie malnutrition. Its olive oil-based lipid component may be associated with fewer infections compared to traditional soybean-based emulsions and may help preserve immune function[1][5][10]. The mechanism of action is nutritional support via intravenous administration.

Brand names
Oliclinomel N7-1000Oliclinomel N7-1000EOLICLINOMEL
Other names
Oliclinomel N71000Oliclinomel N7-1000E

Beyond the preview

Go deeper on oliclinomel n7-1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oliclinomel n7-1000.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call